Some CEOs encourage tension between sales and marketing. A more effective model is for the CRO and CMO to build enough trust to handle all disagreements—like lead quality or follow-up—behind closed doors. This prevents a culture of finger-pointing and presents a united front to leadership.

A common failure mode for new CROs is attempting to create the sales playbook in isolation. Core pillars like ICP and value proposition are company-level decisions. The CRO's role is to be interdependent, facilitating this cross-functional creation process, not dictating it.

The most effective CRO partnerships transcend a simple client-vendor dynamic. Success hinges on viewing the CRO as an integrated part of the research team, fostering close collaboration in study design and maintaining open, continuous communication.

Having a CRO oversee both sales and marketing provides the CEO with a single person accountable for revenue. This structure prevents the common scenario where marketing hits its pipeline goal but sales misses its revenue target. It consolidates ownership of pipeline generation and closing under one leader.

If the board questions a marketing decision you made collaboratively with sales, the most effective response is for the CRO to intervene and publicly defend it. This demonstrates true alignment and shifts the focus from marketing cost to shared business impact.

In a conflict between CEO and CRO directives, a CMO's safest tactical move is to side with the CRO. The sales team is your primary internal customer, and their success dictates your success. You can get fired while hitting all your CEO-mandated goals if the sales team comes for you.

At Informatica, the CEO made the CMO solely responsible for the company's entire sales pipeline. This shifts marketing's focus from departmental metrics (like MQLs) to the ultimate business outcome, forcing deep alignment with the CRO and sales organization.

For smaller biotechs, the key to a successful CRO relationship is treating them as a genuine partner. This requires moving beyond a transactional, fear-based dynamic to one of open communication and mutual respect. Biotechs should actively solicit CRO feedback, as they possess valuable cross-industry insights and can identify sponsor-side behaviors that need to change.

Many new CROs hesitate to challenge the CEO on company strategy. This is a mistake. A CRO's value is providing their unique market perspective as a peer on the executive team, even when it creates friction. This candor is essential for the company's success.